An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients
This study aimed to streamline the MS-MRD process using automated data analysis and dia-PASEF technology. By developing a workflow to identify unique patient-specific protein targets and quantify M-protein levels, the analysis achieved comparable results to PRM methods. Importantly, the new approach significantly reduced assay development time through multiplexing, bringing MS-MRD into clinical implementation.